338 related articles for article (PubMed ID: 17661712)
1. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
[TBL] [Abstract][Full Text] [Related]
5. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
Roylance R; Seddon B; McTiernan A; Sykes K; Daniels S; Whelan J
Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):572-6. PubMed ID: 17624747
[TBL] [Abstract][Full Text] [Related]
6. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Le Cesne A
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Gordon EM; Sankhala KK; Chawla N; Chawla SP
Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
Schöffski P; Dumez H; Wolter P; Stefan C; Wozniak A; Jimeno J; Van Oosterom AT
Expert Opin Pharmacother; 2008 Jun; 9(9):1609-18. PubMed ID: 18518789
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin in soft tissue sarcomas.
Petek BJ; Loggers ET; Pollack SM; Jones RL
Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
[TBL] [Abstract][Full Text] [Related]
10. Unique features of trabectedin mechanism of action.
Larsen AK; Galmarini CM; D'Incalci M
Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
[TBL] [Abstract][Full Text] [Related]
11. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
Cuevas C; Francesch A
Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin's contribution to the treatment of sarcomas.
Blay JY
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
[TBL] [Abstract][Full Text] [Related]
13. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
14. Going further in the knowledge of Yondelis®; what's new in clinical trials?
Blay JY
Future Oncol; 2014 Jun; 10(8 Suppl):s7-s12. PubMed ID: 25048046
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769
[TBL] [Abstract][Full Text] [Related]
16. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Martin-Liberal J; Judson I
Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.
Schmitt T; Keller E; Dietrich S; Wuchter P; Ho AD; Egerer G
Mar Drugs; 2010 Oct; 8(10):2647-58. PubMed ID: 21116412
[TBL] [Abstract][Full Text] [Related]
18. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]